보건행정학회지 (Health Policy and Management)

  • 제23권3호
  • /
  • Pages.210-223
  • /
  • 2013
  • /
  • 1225-4266(pISSN)
  • /
  • 2289-0149(eISSN)
한국보건행정학회 (Korean Academy of Health Policy and Management)
권호 표지
DOI QR코드

DOI QR Code

주요국의 제네릭 의약품 활성화 정책 고찰과 시사점

Lessons from Generic Promotion Policies in Other Countries

  • 김동숙 (건강보험심사평가원 심사평가연구실) ;
  • 배승진 (이화여자대학교 약학대학) ;
  • 장선미 (인제대학교 약학대학)
  • 투고 : 2012.09.19
  • 심사 : 2013.09.06
  • 발행 : 2013.09.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Backgrounds: Escalating pharmaceutical expenditure has threatened the sustainability of National Health Insurance system in Korea. Generic medicines allow patients to access safe, effective, high-quality medicines at low cost, thus insurers could achieve significant financial savings by promotion of generics, if they are priced much lower than the originator. The purpose of this study was to review generic pricing as well as promotion policies in other countries and assess the implication of those policies. Methods: We reviewed the main measures adopted by the developed countries such as Austria, Belgium, Denmark, Finland, France, Germany, Italy, Japan, Netherlands, Norway, Sweden, United Kingdom, especially in countries where governments are the largest third-party payers or insurance finance resource is the national health insurance. Results: The foreign countries's experience with generic medicine policy shows that demand-side policies such as physician budgets, international nonproprietary name prescribing, generics substitution, patients co-payment as well as supply-side policies relating to pricing and reimbursement seems to play a critical role in developing the generic medicines market. Conclusion: Various strategy should be implemented to promote generic drug use.

키워드

참고문헌

  1. U.S. Food and Drug Administration Center for Drug Evaluation and Research. Generic drugs [Internet]. San Clemente (CA): MedicineNet Inc. [cited 2013 Aug 19]. Available from: http//www.medterms.com.
  2. Shin JY, Choi SE. The volume and the price of generic drug consumption in Korea prescription drug market. Korean J Health Econ Policy 2008; 14(1):103-125.
  3. Simoens S, de Coster S. Sustaining generic medicines markets in Europe. New York: Palgrave Macmillan; 2006.
  4. Kim DS, Byun JO, Kim SK, Lee BL, Jang SM, Park CS, et al. The review of prescribing pattern analysis: focused on prescribing indicator. Seoul: Health Insurance Review & Assessment Service; 2009.
  5. Mo H. Pricing policy revision. News Report. 2011 Aug 22.
  6. Organization for Economic Cooperation and Development. OECD health data. Paris: Organization for Economic Cooperation and Development; 2009.
  7. European Generic Medicines Association. How to increase patient access to generic medicines in European healthcare systems. Brussels: European Generic Medicines Association; 2009.
  8. IMS Health. Pharmaceutical pricing & reimbursement. Cambridge: IMS Health; 2008.
  9. Organization for Economic Cooperation and Development. Pharmaceutical pricing and reimbursement policy in Germany. Paris: Organization for Economic Cooperation and Development; 2008.
  10. Organization for Economic Cooperation and Development. Pharmaceutical pricing and reimbursement policy in Sweden. Paris: Organization for Economic Cooperation and Development; 2007.
  11. Pharmaceutical Pricing and Reimbursement Information. Pharmaceutical Pricing and Reimbursement Information Project (PPRI): Austria pharma profile. Vienna: Pharmaceutical Pricing and Reimbursement Information; 2008.
  12. Pharmaceutical Pricing and Reimbursement Information. Pharmaceutical Pricing and Reimbursement Information Project (PPRI): Belgium pharma profile. Vienna: Pharmaceutical Pricing and Reimbursement Information; 2008.
  13. Pharmaceutical Pricing and Reimbursement Information. Pharmaceutical Pricing and Reimbursement Information Project (PPRI): Denmark pharma profile. Vienna: Pharmaceutical Pricing and Reimbursement Information; 2008.
  14. Pharmaceutical Pricing and Reimbursement Information. Pharmaceutical Pricing and Reimbursement Information Project (PPRI): Finland pharma profile. Vienna: Pharmaceutical Pricing and Reimbursement Information; 2007.
  15. Pharmaceutical Pricing and Reimbursement Information. Pharmaceutical Pricing and Reimbursement Information Project (PPRI): France pharma profile. Vienna: Pharmaceutical Pricing and Reimbursement Information; 2008.
  16. Pharmaceutical Pricing and Reimbursement Information. Pharmaceutical Pricing and Reimbursement Information Project (PPRI): Germany pharma profile. Vienna: Pharmaceutical Pricing and Reimbursement Information; 2008.
  17. Pharmaceutical Pricing and Reimbursement Information. Pharmaceutical Pricing and Reimbursement Information Project (PPRI): Italy pharma profile. Vienna: Pharmaceutical Pricing and Reimbursement Information; 2007.
  18. Pharmaceutical Pricing and Reimbursement Information. Pharmaceutical Pricing and Reimbursement Information Project (PPRI): Norway pharma profile. Vienna: Pharmaceutical Pricing and Reimbursement Information; 2008.
  19. Choi YJ, Choi SE. The review of pharmaceutical reimbursement policy. Seoul: Health Insurance Review & Assessment Service; 2009.
  20. Bae SJ, Lim JH, Bae EY. The review of pharmaceutical pricing policy: focused on re-evaluation of other countries. Seoul: Health Insurance Review & Assessment Service; 2009.
  21. Dylst P, Vulto A, Simoens S. Reference pricing systems in Europe: characteristics and consequences. GaBI Journal [Internet]. 2012;1(3-4):127-131 [cited 2013 Aug 19]. Available from: http://gabi-journal.net/reference-pricing-systems-in-europe-characteristics-and-consequences.html. https://doi.org/10.5639/gabij.2012.0103-4.028
  22. Aaserud M, Dahlgren AT, Kosters JP, Oxman AD, Ramsay C. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies. Oxford: The Cochrane Library; 2009.
  23. Vogler S. The impact of pharmaceutical pricing and reimbursement policies on generics uptake: implementation of policy options on generics in 29 European countries-an overview. GaBi J 2012;1(2):93-100. https://doi.org/10.5639/gabij.2012.0102.020
  24. Vogler S, Zimmermann N, Leopold C, de Joncheere K. Pharmaceutical policies in European countries in response to the global financial crisis. South Med Rev 2011;4(2):69-79. https://doi.org/10.5655/smr.v4i2.1004
  25. Schwermann T, Greiner W, v d Schulenburg JM. Using disease manage ment and market reforms to address the adverse economic effects of drug budgets and price and reimbursement regulations in Germany. Value Health 2003;6 Suppl 1:S20-S30. https://doi.org/10.1046/j.1524-4733.6.s1.3.x
  26. Towse A. The efficient use of pharmaceuticals: does Europe have any lessons for a Medicare drug benefit? Health Aff (Millwood) 2003;22(3):42-45. https://doi.org/10.1377/hlthaff.22.3.42
  27. Lee SM, Jang SY, Jang SM. The review of pharmaceutical volume control policy. Seoul: Health Insurance Review & Assessment Service; 2010.
  28. Austvoll-Dahlgren A, Aaserud M, Vist G, Ramsay C, Oxman AD, Sturm H, et al. Pharmaceutical policies: effects of cap and co-payment on rational drug use. Cochrane Database Syst Rev 2008;(1):CD007017.
  29. Penna P. Three-tier copay systems and consumer-centric care. J Manag Care Pharm 2000;6(5):351-353.
  30. Health Insurance Review & Assessment Service, National Health Insurance Service. Health insurance statistics. Seoul: Health Insurance Review & Assessment Service; 2001-2010.
  31. Barros PP. Pharmaceutical policies in European countries. Adv Health Econ Health Serv Res 2010;22:3-27. https://doi.org/10.1108/S0731-2199(2010)0000022004
  32. Godman B, Shrank W, Andersen M, Berg C, Bishop I, Burkhardt T, et al. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications. Expert Rev Pharmacoecon Outcomes Res 2010;10(6):707-722. https://doi.org/10.1586/erp.10.72
  33. Vogler S, Zimmermann N. The potential of generics policies: more room for exploitation: PPRI conference report. GaBI Journal 2012;1(3-4):146-149. https://doi.org/10.5639/gabij.2012.0103-4.030
  34. Boston Consulting Group. Ensuring cost-effective access to innovative pharmaceutical: do market interventions work? Boston (MA): The Boston Consulting Group; 1999.
  35. Kim SK, Kwon SM, Jung Y, Heo JH. International comparison of generic medicine price. Korean J Health Econ Policy 2010;16(3):41-62.